Supplementary Figures and Figure Legends from Targeting p300/CBP Attenuates Hepatocellular Carcinoma Progression through Epigenetic Regulation of Metabolism

Supplementary Figure S1. p300 is a potential target in HCC. Supplementary Figure S2. B029-2 is a potential and selective catalytic p300/CBP inhibitor that targets HCC.Supplementary Figure S3. Targeting p300 suppresses the cell-proliferation of HCC cells.Supplementary Figure S4. B029-2 regulates the expression of ribosome protein genes.Supplementary Figure S5. The expression status of metabolic enzymes in liver hepatocellular carcinoma (LIHC) patients.Supplementary Figure S6. Epigenetic regulation of metabolic enzymes in HCC via the histone acetyltransferase activity of p300/CBP.Supplementary Figure S7. B029-2 treatment reduced the occupation of p300 and BRD4 on the promoters of the six metabolic genes.Supplementary Figure S8. Suppressing the expression of PSPH and DTYMK inhibits HCC progression.Supplementary Figure S9. Overexpression of PSPH and DTYMK partially reversed the inhibitory effects of B029-2 on HCC cells.Supplementary Figure S10. Overexpression of PSPH and DTYMK partially reversed the inhibitory effects of B029-2 on HCC xenografts.